Kintsugi

Kintsugi is a technology company.

Active

Updated: Feb 17, 2026 ·

Recent News & Mentions

Feb 1, 2022FundingKintsugi - Series A Aug 1, 2021FundingKintsugi - Seed Nov 1, 2020FundingKintsugi - Seed Aug 1, 2020FundingKintsugi - Seed

Financial History

Kintsugi has raised $29.0M across 4 funding rounds. Most recently, it raised $20.0M Series A in February 2022.

Total Raised

$29.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Feb 1, 2022	$20.0M Series A	Darling Ventures
Aug 1, 2021	$8.0M Seed	Acrew Capital, Darling Ventures, DST Global, GE Ventures, Andrew Wheeler, MS&AD Ventures, Marc van den Berg, Sequoia Capital, UP.Partners, Ron Pragides
Nov 1, 2020	$1.0M Seed	Darling Ventures
Aug 1, 2020	$20K Seed	Headwater Ventures, Innova Memphis

Financial History

Kintsugi has raised $29.0M across 4 funding rounds.

Total Raised

$29.0M

Valuation

N/A

Deep Dive

High-Level Overview

Kintsugi is a health technology company developing AI-driven voice biomarker software to detect signs of depression and anxiety from short clips of free-form speech, enabling scalable mental healthcare access.[1][2][3][5][6] Its primary product, Kintsugi Voice (KiVA), is an API-first platform that integrates with call centers, telehealth systems, and remote patient monitoring apps, serving health systems, payers, providers, and enterprises by providing real-time, language-agnostic mental health screenings without relying on speech content.[2][3][4][6] The technology addresses gaps in traditional screening methods like PHQ-9 and GAD-7 questionnaires, helping clinicians triage patients faster and improve outcomes amid rising mental health needs, with integrations already in Fortune 500 care management call centers.[3][6] Founded in 2019, Kintsugi has raised over $26.5 million by 2022, earned recognitions like Forbes’ Top 50 AI Companies (2022) and Gartner Cool Vendor, and demonstrated growth through NSF grants and awards.[1][3][4][5][6]

Origin Story

Kintsugi was co-founded in 2019 by Grace Chang, a software engineer and CEO, and Rima Seiilova-Olson, a machine learning scientist, both motivated by personal challenges accessing quality mental health services through their healthcare providers.[3][5] Based in the Bay Area, California, the duo combined their expertise to create AI voice biomarker technology, drawing inspiration from the Japanese art of kintsugi—repairing broken ceramics with gold to make them stronger and more beautiful—symbolizing improved mental health access.[5][6] A pivotal early moment came in October 2019 with a Phase I NSF grant for AI development, followed by 2020 NSF I-Corps participation that refined their go-to-market strategy through customer discovery.[4][5] Initial traction built via KiVA's integration into clinical workflows, leading to $8 million in seed funding and a $20 million Series A in 2022 (totaling over $26.5 million), fueling team expansion in marketing, business, and operations.[3][4]

Core Differentiators

Language-Agnostic Voice Analysis: Detects biomarkers in vocal patterns (e.g., tone, rhythm) from just 20 seconds of speech, trained on the world's largest annotated dataset from 250+ cities, without natural language processing or content interpretation.[2][3][4]
Seamless API Integration: KiVA embeds into existing systems like call centers and telehealth for real-time scoring, anonymizing data and augmenting non-specialists (e.g., nurses, GPs) for faster triage.[1][2][3][6]
Ethical AI and Compliance: HIPAA and HITRUST certified, with accolades for responsible AI (Gartner Cool Vendor 2022, Frost & Sullivan Innovation Award), prioritizing equitable, bias-reduced mental health screening.[2][6]
Proven Scalability: Deployed in enterprise settings like Fortune 500 call centers, outperforming traditional surveys by enabling proactive care during high-demand periods like the pandemic.[3][6]

(Note: A separate sales tax compliance company named Kintsugi exists for ecommerce/SaaS but is unrelated to this health tech firm.[7])

Role in the Broader Tech Landscape

Kintsugi rides the AI-for-healthcare wave, specifically vocal biomarkers amid a mental health crisis where depression affects 80% of chronic conditions and traditional screenings falter under scale demands.[3][6] Timing aligns with post-pandemic telehealth booms and AI adoption in clinical decision support, as payers and providers seek efficient triage to cut costs and save lives—e.g., integrating with remote monitoring to flag risks instantly.[1][3] Market tailwinds include exploding demand for non-invasive diagnostics, regulatory support for AI (e.g., NSF backing), and shifts from reactive to predictive care, positioning Kintsugi to influence ecosystems by standardizing voice-based mental health screening across global health systems.[4][5][6]

Quick Take & Future Outlook

Kintsugi is poised to expand KiVA into pharmaceuticals and SMEs, leveraging its $20M+ funding for global scaling and deeper integrations amid AI health tech maturation.[3][4] Trends like multimodal AI (combining voice with wearables) and value-based care will amplify its edge, potentially evolving it into a mental health platform leader as voice data standards emerge. With ethical AI leadership, expect growing influence in closing care gaps—transforming "broken" access into resilient, gold-standard screening, true to its name.

Sources

Frequently Asked Questions

How much funding has Kintsugi raised?

Kintsugi has raised $29.0M in total across 4 funding rounds.

Who are Kintsugi's investors?

Kintsugi's investors include Darling Ventures, Acrew Capital, DST Global, GE Ventures, Andrew Wheeler, MS&AD Ventures, Marc van den Berg, Sequoia Capital, UP.Partners, Ron Pragides, Headwater Ventures, Innova Memphis.